48 - References

References

48 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

1. Robinson DG, et al. Psychopharmacological treatment in the RAISE-­ETP study: outcomes of a manual and computer decision support system based intervention. Am J Psychiatry 2018; 175:169–179.
2. Zhu Y, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-­analyses. Lancet Psychiatry 2017; 4:694–705.
3. Zhang JP, et al. Efficacy and safety of individual second-­generation vs. first-­generation antipsychotics in first-­episode psychosis: a systematic review and meta-­analysis. Int J Neuropsychopharmacol 2013; 16:1205–1218.
4. Leucht S, et al. Early-­onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005; 57:1543–1549.
5. Agid O, et al. The ‘delayed onset’ of antipsychotic action: an idea whose time has come and gone. J Psychiatry Neurosci 2006; 31:93–100.
6. Kahn RS, et al. Amisulpride and olanzapine followed by open-­label treatment with clozapine in first-­episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-­phase switching study. Lancet Psychiatry 2018; 5:797–807.
7. Subotnik KL, et al. Long-­acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first ­episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 2015; 72:822–829.
8. Schreiner A, et  al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res 2015; 169:393–399.
9. Alphs L, et al. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-­onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry 2018; 12:55–65.
10. Kane JM, et al. Patients with early-­phase schizophrenia will accept treatment with sustained-­release medication (long-­acting injectable anti­ psychotics): results from the recruitment phase of the PRELAPSE trial. J Clin Psychiatry 2019; 80:18m12546.
11. Agid O, et al. An algorithm-­based approach to first-­episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011; 72:1439–1444.
12. Drosos P, et al. One-­year outcome and adherence to pharmacological guidelines in first-­episode schizophrenia: results from a consecutive cohort study. J Clin Psychopharmacol 2020; 40:534–540.
13. Rajalingham K. Clozapine delay results in poorer outcomes for treatment-­resistant schizophrenia patients. Psiquiatría Biológica 2024; 31:100493.
14. Davis JM, et al. A meta-­analysis of the efficacy of second-­generation antipsychotics. Arch Gen Psychiatry 2003; 60:553–564.
15. Leucht S, et al. Second-­generation versus first-­generation antipsychotic drugs for schizophrenia: a meta-­analysis. Lancet 2009; 373:31–41.
16. Schooler N, et  al. Risperidone and haloperidol in first-­episode psychosis: a long-­term randomized trial. Am J Psychiatry 2005; 162:947–953.
17. Oosthuizen PP, et al. Incidence of tardive dyskinesia in first-­episode psychosis patients treated with low-­dose haloperidol. J Clin Psychiatry 2003; 64:1075–1080.
18. Whiskey E, et al. Evaluation of an antipsychotic information sheet for patients. Int J Psychiatry Clin Pract 2005; 9:264–270.
19. Stroup TS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009; 107:1–12.
20. Olofinjana B, et al. Antipsychotic drugs: information and choice: a patient survey. Psychiatr Bull 2005; 29:369–371.
21. Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611–622.
22. Haro JM, et al. Remission and relapse in the outpatient care of schizophrenia: three-­year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006; 26:571–578.
23. Novick D, et al. Recovery in the outpatient setting: 36-­month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009; 108:223–230.
24. Tiihonen J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-­up study. BMJ 2006; 333:224.
25. Leucht S, et al. A meta-­analysis of head-­to-­head comparisons of second-­generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.
26. Remington G, et al. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia. Schizophr Res 2007; 90:229–237.
27. McCutcheon R, et al. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand 2018; 137:39–46.
28. Takeuchi H, et  al. Does relapse contribute to treatment resistance? Antipsychotic response in first-­ vs. second-­episode schizophrenia. Neuropsychopharmacology 2019; 44:1036–1042.
29. McEvoy JP, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600–610.
30. Lewis SW, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-­generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32:715–723.
31. Mace S, et al. Positive views on antipsychotic long-­acting injections: results of a survey of community patients prescribed antipsychotics. Ther Adv Psychopharmacol 2019; 9:2045125319860977.